Clinical Trial Update: Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the combination of imatinib mesylate and decitabine for chronic myeloid leukemia, including accelerated- and blastic-phase di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Accelerated-phase Chronic Myeloid Leukemia
• Blastic-phase Chronic Myeloid Leukemia
• Childhood Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Bcr-abl1 Positive

Drugs mentioned

• Decitabine (Decitabine)
• Imatinib mesylate (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 2 | Status: COMPLETED